Key result
Serum hs-TNT >60 pg/mL (sensitivity 0.79, specificity 0.93) and NT-proBNP >1,000 pg/mL (sensitivity 0.91, specificity 0.93) differentiated cardiac amyloidosis from other infiltrative cardiomyopathies.
Why the study?
Do serum hs-TNT and NT-proBNP levels differentiate light-chain cardiac amyloidosis from Friedreich's ataxia and Fabry disease in patients with infiltrative cardiomyopathy and preserved LV systolic function?
Observational (n=57)
No
Do serum hs-TNT and NT-proBNP levels differentiate light-chain cardiac amyloidosis from Friedreich's ataxia and Fabry disease in patients with infiltrative cardiomyopathy and preserved LV systolic function?
p-value: p=<0.001
Elevated hs-TNT (>60 pg/mL) and NT-proBNP (>1,000 pg/mL) can effectively differentiate light-chain cardiac amyloidosis from other infiltrative cardiomyopathies like Friedreich's ataxia and Fabry disease in patients with preserved LV ejection fraction.
BACKGROUND: This study aimed to explore the value of cardiac biomarker [serum high sensitive troponin T (hs-TNT) and N-terminal pro-brain natriuretic peptide (NT-proBNP)] measurement in the differential diagnosis of infiltrative cardiomyopathy patients [Friedreich's ataxia (FA), Fabry disease (FD) and light-chain (AL) cardiac amyloidosis (CA)] with preserved left ventricular (LV) systolic function. METHODS: Between 2012 and 2014, all consecutive patients presenting at our center with infiltrative cardiomyopathy and concomitant symmetrical LV hypertrophy as well as preserved LV systolic function were included in this study. Serum hs-TNT and NT-proBNP, morphologic and functional features derived from echocardiography and cardiac magnetic resonance imaging (cMRI) examinations were compared among these patients. RESULTS: A total of 57 patients (FA 20, FD 23 and CA 14) were included. Hs-TNT and NT-proBNP levels were significantly higher in the CA group [median: hs-TNT 98 pg/mL, NT-proBNP 4,110 pg/mL] than in the FA group [hs-TNT 14 pg/mL, NT-proBNP 40 pg/mL] and FD group [hs-TNT 18 pg/mL, NT-proBNP 131 pg/mL, both P<0.001]. There was a negative correlation between NT-proBNP and estimated glomerular filtration rate (eGFR) in CA patients (r=-0.72, P=0.012). Both hs-TNT >60 pg/mL (sensitivity 0.79, specificity 0.93) and NT-proBNP >1,000 pg/mL (sensitivity 0.91, specificity 0.93) excellently differentiated CA from FA and FD. CONCLUSIONS: Increased hs-TNT and NT-proBNP levels are suggestive of CA diagnosis among patients with infiltrative cardiomyopathy and preserved LV ejection fraction.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2018) conducted an observational in Infiltrative cardiomyopathy with preserved left ventricular systolic function (n=57). Serum hs-TNT and NT-proBNP measurement vs. Friedreich's ataxia and Fabry disease was evaluated on Differentiation of cardiac amyloidosis from Friedreich's ataxia and Fabry disease (p=<0.001). Serum hs-TNT >60 pg/mL (sensitivity 0.79, specificity 0.93) and NT-proBNP >1,000 pg/mL (sensitivity 0.91, specificity 0.93) differentiated cardiac amyloidosis from other infiltrative cardiomyopathies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: